Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792 is registered in ClinicalTrials.gov with ReAlta Life Sciences, Inc. as lead sponsor.

NCT NCT06343792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06343792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
Lead sponsor
ReAlta Life Sciences, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 31, 2024
Completion date
December 31, 2026
Enrollment
66 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

steroid refractory gvhd